Management of complicated facial hemangiomas with beta-blocker (propranolol) therapy

Plastic and Reconstructive Surgery

Volumn 127, Issue 4, 2011, Pages 1742-1743

  Mishra, Anuj ^a   Holmes, William ^a   Gorst, Catherine ^a   Liew, Sehwang ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL;

FACE TUMOR; HEMANGIOMA; HUMAN; INFANT; NOTE;

ADRENERGIC BETA-ANTAGONISTS; FACIAL NEOPLASMS; HEMANGIOMA; HUMANS; INFANT; PROPRANOLOL;

EID: 79954988573     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31820a656a     Document Type: Letter

References (4)

1. Arneja JS, Pappas PN, Shwayder T, et al. Management of complicated facial hemangiomas with beta-blocker (propranolol) therapy. Plast Reconstr Surg. 2010;126:889-895.
2. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as firstline treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. (in press).
3. O T, Waner M, Xu D, et al. Vandetanib and propranolol inhibit infantile hemangioma (IH) and NICH cell growth in vitro. Presented at: 18th International Workshop on Vascular Anomalies; April 21-24, 2010; Brussels, Belgium.
4. Yang Q, Kumar S, Salalto V, Szabo S, North PE. Propranolol inhibits proliferation and tube formation by purified placental capillary endothelial cells, an in vitro model for infantile hemangioma (IH), and induces their apoptosis. Presented at: 18th International Workshop on Vascular Anomalies; April 21-24, 2010; Brussels, Belgium.